Do you want to skip to content? Skip to content
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec

Most visited pages

Reports, results and presentations
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

02 August 2018

Download Full Press Release

PDF Download

 

Convatec Group Plc First Half Results 2018

Solid performance - full year guidance confirmed


Convatec Group Plc and its subsidiaries ("Convatec" or the "Group"), a leading global medical products and technologies company focused on therapies for the management of chronic conditions, today reports first half results for the six months ended 30 June 2018 in line with expectations, with guidance for the full year confirmed, despite a challenging environment in certain key markets.

Key points:

  • Group reported revenue of $921.3 million grew 10.8% year on year, 6.4%2 CER or 2.6%3 organically;
  • Mixed results in Advanced Wound Care with a strong performance in AQUACELTM Foam and Silver offset by challenges in our older DuoDERMTM and base AQUACELTM dressings; good recovery in Ostomy Care and strong organic revenue growth from Continence & Critical Care and Infusion Devices;
  • Good progress on reducing backorders – now at normal level;
  • Adjusted1 gross margin % decreased by 100 bps, 30 bps negative foreign exchange impact and 70 bps operational impact, as a result of expected headwinds. Reported gross margin increased 50 bps due to lower restructuring costs year on year.
  • Reported operating profit / EBIT $122.0 million, an increase of 31.5% year on year;
  • Adjusted1 operating profit / EBIT $203.5 million, 5.2% higher year on year; Adjusted1 EBIT margin 22.1% (2017: 23.3%), in line with expectations;
  • Interim dividend 1.717 cents, payout ratio of 35% of adjusted net income (annualised), in line with policy;
  • Guidance for the full year confirmed: organic revenue growth 2.5% - 3.0%, adjusted EBIT margin 24% – 25%.

Paul Moraviec, Group Chief Executive Officer, commented:

“In the first half of 2018, we delivered a solid performance and made good progress in many areas. Our Continence & Critical Care and Infusion Devices franchises delivered strong results and in the second quarter Ostomy Care returned to positive organic revenue growth. Within Advanced Wound Care we have seen strong demand for our newer Foam and Silver dressings, although this was offset by headwinds in our older DuoDERMTM hydrocolloid and base AQUACELTM dressings, as a result of the supply constraints of last year and challenging market dynamics. However, recent positive trends and early results from our growth initiatives give us confidence that we will see an improved performance in Advanced Wound Care in the second half.

“The backorders which arose last year continued to fall during the second quarter and are now at a normal level, as planned. Despite the modest decline in adjusted gross margin in the first half, we are making good progress with our cost out programmes. We continue to invest in the commercial areas of the business and in new product development, whilst further reducing leverage. We are well positioned to deliver on our plans during the remainder of the year and consequently our guidance for the full year is unchanged.”

 

Franchise Summary

Group reported revenue grew 10.8% in the first six months of 2018, 6.4%2 CER or 2.6%3 organically and 8.1% reported growth in the second quarter, 5.3% CER2 or 1.7%3 organically.

  • Advanced Wound Care (“AWC”) revenue grew 6.6% on a reported basis, or 1.0%3 organically in the first half of 2018, and grew 3.3% on a reported basis and declined by 0.2%3 organically, in the second quarter. Our AQUACELTM Foam and anti-biofilm Silver platforms performed well, offset by challenges in our older DuoDERMTM and base AQUACELTM dressings as a result of the supply constraints of last year and challenging market dynamics, most notably in the UK. Performance in the US post-acute channel continues to be a drag on growth, and we are taking action by rolling out a national US wound acceleration plan. We anticipate an improved performance from AWC in the second half of the year.
  • Ostomy Care (“OC”) revenue grew 4.4% on a reported basis, but declined 1.0%3 organically in the first six months of 2018, and in the second quarter grew by 3.8% on a reported basis or 0.3%3 organically. We made further progress in reducing orders on hold in the second quarter, which provided a tailwind to performance. We continue to execute our strategy to return the franchise to consistent growth, with a good performance in Latin America and Asia Pacific and positive trends in some European markets.
  • Continence & Critical Care (“CCC”) revenue grew 25.7% on a reported basis, 23.4%2 CER or 5.7%3 organically in the first half of 2018, and by 24.7% on a reported basis, 23.3%2 CER or 5.9%organically in the second quarter, with a strong Continence Care performance from our Home Distribution Group (“HDG”) being partially offset by planned product rationalisation, which reduced CCC revenue by c. $1 million in the first half.
  • Infusion Devices (“ID”) revenue grew 12.2% on a reported basis, 9.2%3 organically, in the first half of 2018 and by 4.6% on a reported basis and 2.7%3 organically in the second quarter, a strong performance driven by one-off tailwinds and continued growth in the insulin pump market.

 

Download the full text of this announcement and the presentation for the analyst and investors meeting.

 

Enquiries

 
Analysts and Investors                                                                                  

investorrelations@convatec.com

John Crosse, VP Investor Relations

+44 (0)7500 141435

Kirsty Law, Director Investor Relations     

+44 (0)7470 909582

Media


mediarelations@convatec.com

Bobby Leach, VP Group Corporate Affairs                      

+44 (0)7770 842226

Finsbury

+44 (0)207 2513801

 

 

Financial Calendar                                                                                      

                                                              

Ex-dividend date

6 September 2018

Dividend record date

7 September 2018

Script dividend election date

21 September 2018

Dividend payment date

12 October 2018

Q3 trading update

31 October 2018

 

Press Release

See all

5/13/2022

5/13/2022

Q1 Trading Update for the three months ended 31 March 2018

Q1 Trading Update for the three months ended 31 March 2018

Read more

5/13/2022

5/13/2022

Convatec announces changes within its U.S. Home Distribution Group

Convatec announces changes within its U.S. Home Distribution Group

Read more

5/13/2022

5/13/2022

Convatec announces 2018 Interim Results

Convatec announces 2018 Interim Results

Read more

5/13/2022

5/13/2022

03 July 2018 - Board Changes

03 July 2018 - Board Changes

Read more

5/13/2022

5/13/2022

Convatec Receives U.S. FDA 510(k) Clearance for Avelle™ Negative Pressure Wound Therapy System

Convatec Receives U.S. FDA 510(k) Clearance for Avelle™ Negative Pressure Wound Therapy System

Read more

5/13/2022

5/13/2022

Trading update for the three months ended 30 September 2018 and change in FY 2018 guidance

Trading update for the three months ended 30 September 2018 and change in FY 2018 guidance

Read more

5/13/2022

5/13/2022

Retirement of Chief Executive Officer and appointment of Rick Anderson as Chief Executive Officer (Interim)

Retirement of Chief Executive Officer and appointment of Rick Anderson as Chief Executive Officer (Interim)

Read more

5/13/2022

5/13/2022

US FDA 510(k) clearance for AQUACEL™ Ag Advantage

US FDA 510(k) clearance for AQUACEL™ Ag Advantage

Read more

5/13/2022

5/13/2022

Convatec Welcomes Wound Care Sector Deal

Convatec Welcomes Wound Care Sector Deal

Read more